Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19

Abstract We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvo...

Full description

Bibliographic Details

Published in:	Open forum infectious diseases Vol. 8; no. 2; p. ofab050
Main Authors:	Seftel, David, Boulware, David R
Format:	Journal Article
Language:	English
Published:	US Oxford University Press 01.02.2021
Subjects:	Brief Report Editor's Choice COVID-19 cohort coronavirus fluvoxamine SARS-COV-2
ISSN:	2328-8957, 2328-8957
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!